Investors

Company Profile

Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.

Financial Reports

Q3 Report 2019

November 7, 2019

Q2 Report 2019

August 7, 2019

Q1 Report 2019

May 9, 2019

Investor presentations

Linzagolix Phase 3 PRIMROSE 2 Trial Results

Investor Presentation 10th Annual Jefferies Global Healthcare Conference 21 November 2019

Investor Presentation November 2019

Cantor Global Healthcare Conference October 4 2019

The H.C. Wainwright 21st Annual Global Investment in NYC – September 10th 2019

Wedbush Presentation August 2019 in NYC

KOL Event in NYC July 2019

Jefferies Healthcare Conference Presentation – June 2019

1 2

Press Releases

ObsEva Strengthens Board with Appointment of Biotechnology Veteran Dr. Frank Verwiel

press release

March 24, 2016

Geneva, Switzerland, 24 March 2016 – ObsEva, a Swiss biopharmaceutical company innovating women’s reproductive health and pregnancy therapeutics, today announced…

Read more

ObsEva Closes CHF 60 (USD 60) Million in Series B Financing

press release

November 23, 2015

Geneva, Switzerland, 23 November 2015 – ObsEva, a Swiss biopharmaceutical company developing a novel generation of drugs addressing serious conditions compromising…

Read more

ObsEva and Kissei Pharmaceutical Announce Global Agreement to Develop and Commercialize KLH-2109 for the Treatment of Endometriosis

press release

November 20, 2015

Geneva, Switzerland, 20 November 2015 – ObsEva and Kissei Pharmaceutical Co., Ltd. (“Kissei”) today announced that they have entered into a…

Read more
1 37 38 39 40 41 43

General Meetings

ObsEva Annual General Meeting 2019

May 8, 2019

Read more

ObsEva Annual General Meeting 2018

May 9, 2018

Read more
1 2

Upcoming Events

Year End 2019 Financial Results week of 02 March 2020

Event

March 2, 2020


Read more
 

Contacts

ObsEva Switzerland Office

+41 (0)22 552 3840


contact@obseva.ch

ObsEva U.S. Office

+1 857 972 9364


contact@obseva.ch

Media Switzerland & Europe

Christophe Lamps
Dynamics Group
+41 79 476 26 87

cla@dynamicsgroup.ch

Media United States

Marion Janic
RooneyPartners LLC
+1 212-223-4017

mjanic@rooneyco.com

Investor relations




ir@obseva.ch

Clinical studies




clinicaltrials@obseva.ch

HR Office

Charlotte Cadoux


charlotte.cadoux@obseva.ch

CEO Office

+41 (0)22 552 1550


shauna.dillon@obseva.ch

 

Sign up for news

 
 

* Type:


InvestorHCPNursePayerHospital PharmacistRetail PharmacistOther












Read our privacy policy here.

 

Are you sure you want to leave ObsEva.com?

We're sorry to see you go.
Choose one of the following actions to stay on the site or leave.

Continue to link

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue